title: Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data.
abstract: Replication-competent (oncolytic) viruses (OV) as cancer immunotherapeutics have gained an increasing level of attention over the last few years while the clinical evidence of virus-mediated antitumor immune responses is still anecdotal. Multiple clinical studies are currently ongoing and more immunomonitoring results are expected within the next five years. All viruses can be recognized by the immune system and are therefore potential candidates for immune therapeutics. However, each virus activates innate immune system by using different combination of recognition receptors/pathways which leads to qualitatively different adaptive immune responses. This review summarizes immunological findings in cancer patients following treatment with replication-competent viruses.
authors.affiliation: 1 Memorial Sloan Kettering Cancer Center , New York, New York.
authors.forename: Dmitriy
authors.initials: D
authors.lastname: Zamarin
authors.affiliation: 2 Oncos Therapeutics , Helsinki, Finland .
authors.forename: Sari
authors.initials: S
authors.lastname: Pesonen
mesh_terms: D000818:Animals; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000628:therapy*; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000502:physiology; D014779:Virus Replication